Skip to main content
SpringerLink
Log in

Anti-IgE and Other Antibody Targets in Asthma

  • Chapter
Therapeutic Antibodies

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 181))

Asthma is a heterogeneous disorder of unknown etiology that manifests as recurrent episodes of coughing, wheezing, and breathlessness. These symptoms are often debilitating and exacerbations usually are unexpected, resulting in work or school absences, limitations in activity, reduced quality of life, and personal and economic hardships.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adis (2002) Omalizumab. Biodrugs 16:380-386

    Google Scholar 

  • Amiri P, Haak-Frendscho M, Robbins K, McKerrow JH, Stewart T, Jardieu P (1994) Antiimmunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med 180:43-51

    PubMed  Google Scholar 

  • Avila PC (2007) Does Anti-IgE Therapy Help in Asthma? Efficacy and Controversies. Annu Rev Med 58

    Google Scholar 

  • Barnes PJ (2003) Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 14:511-522

    PubMed  Google Scholar 

  • Bayram H, Sapsford RJ, Abdelaziz MM, Khair OA (2001) Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients in vitro. J Allergy Clin Immunol 107:287-294

    PubMed  Google Scholar 

  • Beck LA, Marcotte GV, MacGlashan JD, Togias A, Saini S (2004) Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 114:527-530

    PubMed  Google Scholar 

  • Bennett AN, Wong M, Zain A, Panayi G, Kirkham B (2005) Adalimumab-induced asthma. Rheumatology 44:1199-1200

    PubMed  Google Scholar 

  • Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID (2006) Evidence of a role of tumor necrosis factor {alpha} in refractory asthma. N Engl J Med 354:697-708

    PubMed  Google Scholar 

  • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285

    PubMed  Google Scholar 

  • Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan C (2005) Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 95:247-253

    PubMed  Google Scholar 

  • Borish LC, Nelson HS, Corren J, Bensch G, Busse WW (2001) Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 107:963-970

    PubMed  Google Scholar 

  • Bosson J, Stenfors N, Bucht A, Helleday R, Pourazar J, Holgate ST, Kelly FJ, Sandstrom T, Wilson S, Frew AJ, Blomberg A (2003) Ozone-induced bronchial epithelial cytokine expression differs between healthy and asthmatic subjects. Clin Exp Allergy 33:777-782

    PubMed  Google Scholar 

  • Boulet L-P, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, Devault A, Fick RB, Cockcroft DW (1997) Inhibitory effects of an AntiIgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155:1835-1840

    PubMed  Google Scholar 

  • Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302-308

    PubMed  Google Scholar 

  • Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H (2004) Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma. Chest 125:1378-1386

    PubMed  Google Scholar 

  • Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117:1277-1284

    PubMed  Google Scholar 

  • Braman SS (2006) The Global Burden of Asthma. Chest 130:4S-12

    PubMed  Google Scholar 

  • Bresnihan B, Cunnane G (2003) Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 29:185-202

    PubMed  Google Scholar 

  • Broide DH (2001) Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108:S65-S71

    PubMed  Google Scholar 

  • Buhl R (2003) Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir Med 97:123-129

    PubMed  Google Scholar 

  • Buhl R (2004) Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 11:27-34

    Google Scholar 

  • Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-190

    PubMed  Google Scholar 

  • Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ (1997) Use of an anti-IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol 100:110-121

    PubMed  Google Scholar 

  • Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, SeyfertMargolis V, Asare A, Bateman K (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134-140

    PubMed  Google Scholar 

  • Chang TW (2000) The pharmacological basis of anti-IgE therapy. Nat Biotech 18:157-162

    Google Scholar 

  • Chinn S (2006) Obesity and asthma. Paediatr Respir Rev 7:223-228

    PubMed  Google Scholar 

  • Cohen RT, Celedon JC, Hinckson VJ, Ramsey CD, Wakefield DB, Weiss ST, Cloutier MM (2006) Health-Care Use Among Puerto Rican and African-American Children With Asthma. Chest 130:463-471

    PubMed  Google Scholar 

  • Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, Szefler SJ (2004) Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol 114:575-582

    PubMed  Google Scholar 

  • Dillman R (1989) Monoclonal antibodies for treating cancer. Ann Intern Med 111:592-603

    PubMed  Google Scholar 

  • Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG (2006) Allergic rhinitis and sinusitis in asthma: Differential effects on symptoms and pulmonary function. Chest 130:429-435

    PubMed  Google Scholar 

  • Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV (2004) Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593

    PubMed  Google Scholar 

  • Dolan C, Fraher K, Bleecker E, Borish LC, B, Hayden M, Weiss S, Zheng B, Johnson C, Wenzel S (2004) Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92:32-39

    PubMed  Google Scholar 

  • Dolovich J, Hargreave FE, Chalmers R, Shier KJ, Gauldie J, Bienenstock J (1973) Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 52:38-46

    PubMed  Google Scholar 

  • Eder W, Ege MJ, von Mutius E (2006) The asthma epidemic. N Engl J Med 355:2226-2235

    PubMed  Google Scholar 

  • Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT (2006) The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit. Care Med 174:753-762

    PubMed  Google Scholar 

  • Erzurum SC (2006) Inhibition of tumor necrosis factor α for refractory asthma. N Engl J Med 354:754-758

    PubMed  Google Scholar 

  • Fahy J, Cockcroft D, Boulet L, Wong H, Deschesnes F, Dvid E, Ruppel J, Su J, Adelman D (1999) Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 160

    Google Scholar 

  • Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:1828-1834

    PubMed  Google Scholar 

  • Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB (2003a) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029-1036

    Google Scholar 

  • Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003b) Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167:199-204

    Google Scholar 

  • Geiger E, Magerstaedt R, Weendorf JHM, Kraft S, Hanau D, Bieber T (2000) IL-4 induces the intracellular expression of the α chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells. J Allergy Clin Immunol 105:150-156

    PubMed  Google Scholar 

  • Genentech-Inc (2003) Briefing document on safety of omalizumab (Xolair) for treatment of allergic asthma (BLA STN 103976/0). Food and Drug Administration, Washington, DC

    Google Scholar 

  • Genentech (2003) Omalizumab prescribing information. South San Francisco, CA

    Google Scholar 

  • Giles JT, Bathon JM (2004) Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases. J Intensive Care Med 19:320-334

    PubMed  Google Scholar 

  • Gold DR, Wright R (2005) Population disparities in asthma. Ann Rev Public Health 26:89-113

    Google Scholar 

  • Gosset P, Tsicopoulos A, Wallaert B, Vannimenus C, Joseph M, Tonnel A-B, Capron A (1991) Increased secretion of tumor necrosis factor α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 88:561-571

    PubMed  Google Scholar 

  • Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263

    PubMed  Google Scholar 

  • Gulliver T, Eid N (2005) Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults. Immunol Allergy Clin North Am 25:541-555

    PubMed  Google Scholar 

  • Hajiro T, Nishimura K (2002) Minimal clinically significant difference in health status: the thorny path of health status measures? Eur Respir J 19:390-391

    PubMed  Google Scholar 

  • Hakonarson H, Carter C, Kim C, Grunstein M (1999) Altered expression and action of the low-affinity IgE receptor FcεRII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 104:575-584

    PubMed  Google Scholar 

  • Harding (2005) Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin N Am 25:131-148

    Google Scholar 

  • Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34:819-836

    PubMed  Google Scholar 

  • Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19:491-498

    PubMed  Google Scholar 

  • Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638

    PubMed  Google Scholar 

  • Holt P, Macaubas C, Stumbles P, Sly P (1999) The role of allergy in the development of asthma. Nature 402:B12-B17

    PubMed  Google Scholar 

  • Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST (2005) Tumour necrosis factor (TNFα ) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60:1012-1018

    PubMed  Google Scholar 

  • Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K (2005) Benefits of omalizumab as addon therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309-316

    PubMed  Google Scholar 

  • Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ (1997) Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99:657-665

    PubMed  Google Scholar 

  • Hyams JS, Markowitz J, Wyllie R (2000) Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 137:192-196

    PubMed  Google Scholar 

  • Jain S, Bandi V, Officer T, Wolley M, Guntupalli K (2006) Role of vocal cord function and dysfunction in patients presenting with symptoms of acute asthma exacerbation. J Asthma 43:207-212

    PubMed  Google Scholar 

  • Jiang H, Harris MB, Rothman P (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 105:1063-1070

    PubMed  Google Scholar 

  • Jones PW (2002) Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 19:398-404

    PubMed  Google Scholar 

  • Juniper E (1999) Health-related quality of life in asthma. Curr Opin Pulm Med 5:105-110

    PubMed  Google Scholar 

  • Juniper E, Guyatt G, Epstein R, Ferrie P, Jaeschke R, Hiller T (1992) Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47:76-83

    PubMed  Google Scholar 

  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α -neutralizing agent. N Engl J Med 345:1098-1104

    PubMed  Google Scholar 

  • Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542-548

    PubMed  Google Scholar 

  • Kim J, McKinley L, Natarajan S, Bolgos GL, Siddiqui J, Copeland S, Remick DG (2006) Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 36:122-132

    PubMed  Google Scholar 

  • Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:1655-1659

    PubMed  Google Scholar 

  • Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A, Kawakami Y, Liu F-T, Lowell CA, Barisas BG, Galli SJ, Kawakami T (2003) Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcεRI. PNAS 100:12911-12916

    PubMed  Google Scholar 

  • Kroegel C, Julius P, Matthys H, Virchow Jc, Jr., Luttmann W (1996) Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 9:899-904

    PubMed  Google Scholar 

  • Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 42:617-621

    PubMed  Google Scholar 

  • Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann K-C, Rolinck-Werninghaus C, Grave M (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274-280

    PubMed  Google Scholar 

  • Kulczycki A, Isersky C, Metzger H (1974) The interaction of IgE with rat basophilic leukemia cells. I. Evidence for specific binding of IgE. J Exp Med 139:600-616

    PubMed  Google Scholar 

  • Leckie MJ, Brinke At, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148

    PubMed  Google Scholar 

  • Lemanske RF, Jr., Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N (2002) Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110:e55

    PubMed  Google Scholar 

  • Leung DYM, Sampson HA, Yunginger JW, Burks AW, Jr., Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR, Jr., the TNXPASG (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986-993

    Google Scholar 

  • Li Y-F, Gauderman WJ, Avol E, Dubeau L, Gilliland FD (2006) Associations of tumor necrosis factor G-308A with childhood asthma and wheezing. Am J Respir Crit Care Med 173:970-976

    PubMed  Google Scholar 

  • Liu J, Lester P, Builder S, Shire SJ (1995) Characterization of Complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34:10474-10482

    PubMed  Google Scholar 

  • Lugogo NL, Kraft M (2006) Epidemiology of asthma. Clin Chest Med 27:1-15

    PubMed  Google Scholar 

  • MacGlashan D (1993) Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 91:605-615

    PubMed  Google Scholar 

  • MacGlashan DW, Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (1997) Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158:1438-1445

    PubMed  Google Scholar 

  • Malveaux F, Conroy M, Adkinson NJ, LM L (1978) IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 62:176-181

    PubMed  Google Scholar 

  • Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC (2000) Surveillance for Asthma - United States, 1980-1999.

    Google Scholar 

  • Marcus P (2006) Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 129:466-474

    PubMed  Google Scholar 

  • Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ (1995) Asthma and wheezing in the first six years of life. N Engl J Med 332:133-138

    PubMed  Google Scholar 

  • Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G (1995) The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation. J Immunol 154:6285-6290

    PubMed  Google Scholar 

  • Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108:e36

    PubMed  Google Scholar 

  • Milgrom H, Fick R, Su J, Reimann J, Bush R, Watrous M, Metzger W (1999a) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973

    Google Scholar 

  • Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ, The rhu MESG (1999b) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973

    Google Scholar 

  • Mingomataj EC, Xhixha F, Gjata E (2006) Helminths can protect themselves against rejection inhibiting hostile respiratory allergy symptoms. Allergy 61:400-406

    PubMed  Google Scholar 

  • Mukhopadhyay S, Hoidal J, Mukherjee T (2006) Role of TNFα in pulmonary pathophysiology. Respir Res 7:125

    PubMed  Google Scholar 

  • NAEEP (1997) National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH

    Google Scholar 

  • NAEEP (2002) Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics (2002). NIH

    Google Scholar 

  • NHLBI (1991) Guidelines for the Diagnosis and Management of Asthma: I. Definition and diagnosis. J Allergy Clin Immunol 88:427-438

    Google Scholar 

  • NHLBI/WHO (2002) Global Initiative for asthma: global strategy for asthma management and prevention. NIH

    Google Scholar 

  • Oba Y, Salzman GA (2004) Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 114:265-269

    PubMed  Google Scholar 

  • Ober C, Hoffjan S (2006) Asthma genetics 2006: the long and winding road to gene discovery. Genes Immunol 7:95-100

    Google Scholar 

  • Oettgen HC, Geha RS (2001) IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 107:429-440

    PubMed  Google Scholar 

  • Ohkawara Y, Lei XF, Stampfli MR, Marshall JS, Xing Z, Jordana M (1997) Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 16:510-520

    PubMed  Google Scholar 

  • Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou T-T, Ying S, Kay AB (2005) Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116:558-564

    PubMed  Google Scholar 

  • Parks KW, Casale TB (2006) Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc 27:33-36

    Google Scholar 

  • Pennings HJ, Kramer K, Bast A, Buurman WA, Wouters EF (1998) Tumour necrosis factor-alpha induces hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro. Eur Respir J 12:45-49

    PubMed  Google Scholar 

  • Presta L, Shields R, O’Connell L, Lahr S, Porter J, Gorman C, Jardieu P (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368-26373

    PubMed  Google Scholar 

  • Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623-2632

    PubMed  Google Scholar 

  • Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB (2003) Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 112:1147-1154

    PubMed  Google Scholar 

  • Prussin C, Metcalfe DD (2006) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 117:S450-S456

    PubMed  Google Scholar 

  • Qureshi F, Pestian J, Davis P, Zaritsky A (1998) Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 339:1030-1035

    PubMed  Google Scholar 

  • Reeves MJ, Bohm SR, Korzeniewski SJ, Brown MD (2006) Asthma care and management before an emergency department visit in children in Western Michigan: how well does care adhere to guidelines? Pediatrics 117:S118-126

    PubMed  Google Scholar 

  • Rieves D (2003) FDA medical officer’s review of safety information on omalizumab in briefing BLA STN 103976/0. Food and Drug Administration, Washington, DC

    Google Scholar 

  • Roberts NJ, Robinson DS, Partridge MR (2006) How is difficult asthma managed? Eur Respir J 28:968-973

    PubMed  Google Scholar 

  • Roskos LK, Davis CG, Schwab GM (2004) The clinical pharmacology of therapeutic monoclonal antibodies. Drug Development Res 61:108-120

    Google Scholar 

  • Rychly D, DiPiro J (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25:1181-1192

    PubMed  Google Scholar 

  • Saini SS, MacGlashan DW, Jr., Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS (1999) Down-regulation of human basophil IgE and FCεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162:5624-5630

    PubMed  Google Scholar 

  • Schulman ES (2001) Development of a monoclonal anti-immunoglobulin E antibody (Omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164:6S-11

    Google Scholar 

  • Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704-712

    PubMed  Google Scholar 

  • Shields R, Whether W, Zioncheck K, O’Connell L, Fendly B, Presta L, Thomas D, Saban R, Jardieu P (1995) Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 107:308-312

    PubMed  Google Scholar 

  • Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE (2006) Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy, Asthma Immunol 96:406-414

    Google Scholar 

  • Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261

    PubMed  Google Scholar 

  • Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ (1990) Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 323:502-507

    PubMed  Google Scholar 

  • Strunk RC, Bloomberg GR (2006) Omalizumab for Asthma. N Engl J Med 354:2689-2695

    PubMed  Google Scholar 

  • Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske JRF (2003) Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 112:883-892

    PubMed  Google Scholar 

  • Thomas P, Heywood G (2002) Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57:774-778

    PubMed  Google Scholar 

  • Thomas PS, Yates DH, Barnes PJ (1995) Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 152:76-80

    PubMed  Google Scholar 

  • Upham JW (2003) The role of dendritic cells in immune regulation and allergic airway inflammation. Respirology 8:140-148

    PubMed  Google Scholar 

  • van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NHT (2005) First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:465-469

    PubMed  Google Scholar 

  • Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59:709-717

    PubMed  Google Scholar 

  • Walker S, Monteil M, Phelan K, Lasserson T, EHW (2006) Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev

    Google Scholar 

  • Walsh GM (2005) Novel therapies for asthma - advances and problems. Curr Pharm Design 11:3027-3038

    Google Scholar 

  • Walsh GM (2006) Targeting airway inflammation: novel therapies for the treatment of asthma. Curr Med Chem 13:3105-3111

    PubMed  Google Scholar 

  • Wijnhoven HAH, Kriegsman DMW, Hesselink AE, Penninx BWJH, de Haan M (2001) Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life. Chest 119:1034-1042

    PubMed  Google Scholar 

  • Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD (1998) Interleukin-13: central mediator of allergic asthma. Science 282:2258-2261

    PubMed  Google Scholar 

  • Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL, III (2003) Histoplasmosis after Treatment with Anti-Tumor Necrosis Factor-α Therapy. Am J Respir Crit Care Med 167:1279-1282

    PubMed  Google Scholar 

  • Yazdanbakhsh M, van den Biggelaar A, Maizels RM (2001) Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol 22:372-377

    PubMed  Google Scholar 

  • Yigla M, Tov N, Solomonov A, Rubin A, Harlev D (2003) Difficult-to-control asthma and obstructive sleep apnea. J Asthma 40:865-871

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Asthma, Allergy and Airway Center Duke University Medical Center, Durham, NC 27710, USA

    J. Singh & M. Kraft

Authors
  1. J. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kraft
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ARC Chair of Rheumatology, Centre Lead Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre, Charterhouse Square, EC1M 6BQ, London, UK

    Yuti Chernajovsky

  2. Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre, Charterhouse Square, EC1M 6BQ, London, UK

    Ahuva Nissim

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Singh, J., Kraft, M. (2008). Anti-IgE and Other Antibody Targets in Asthma. In: Chernajovsky, Y., Nissim, A. (eds) Therapeutic Antibodies. Handbook of Experimental Pharmacology, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73259-4_12

Download citation

Publish with us

Policies and ethics

Search

Navigation